Search PubMed⌕ Search

Biomedical subjects

A Violante

Publications and source records attributed to A Violante.

53 records · Page 3Linked to original sources
PubMedDate not supplied

Hemodialysis with two sequential hemodialyzers.

BACKGROUND/AIMS: The principal aims of the new hemodialysis methods are: a short-time dialysis session, the increase of solute removal, the patient's well-being and, when possible, the reduction of global costs. Other researchers have experimented the simultaneous use of two hemodialyzers in hemodialysis. We tested a new technique which involves the use of two Cuprophan hemodialyzers in sequence (double filter system: DFS), each one connected separately to fresh dialysate. METHODS: We treated 15 large patients with DFS and compared the results with conventional hemodialysis (CHD). RESULTS: Our results showed a significant difference between CHD and DFS in the depuration values. After the first hemodialyzer, modification of pH and electrolytes occurred in the plasma composition. In the second hemodialyzer, urea depuration occurred without further significant changes in hydroelectrolytic and acid-basic plasma patterns. The Kt/V increased from 1.10 to 1.29 (18%). CONCLUSION: Our technique is conceived for the following goal: to increase the diffusion of solution without increasing costs and side effects.

Adult↗
PubMedDate not supplied

[Interferon-beta 1a in relapsing-remitting multiple sclerosis. First report of a Mexican population].

OBJECTIVE: We present the results of a prospective and a longitudinal study of IFN-beta 1a (Rebif) in the treatment of Mexican patients with relapsing-remittin multiple sclerosis (MS). PATIENTS AND METHODS: Twenty five patients were included, all of them fulfilled the diagnostic criteria proposed by Poser, had a clinical evolution of at least 2 years, had 2 to 3 acute attacks of MS in the 12 months preceding study entry and an EDSS < 5.5. Six patients were excluded from the trial, one because of anaphylactic shock, 2 progressed to the chronic form and 3 decided not to continue in the study. These patients were considered as treatment failures and represented 24% of the participants entering the trial. The remaining 19 patients (mean age 29.8, 74% females) completed 2-year follow-up. The mean time of disease duration was 48.8 months. Six million units of IFN-beta 1a were applied thrice weekly, in 8 patients (42%) dosage reduction to 6 millions units twice a week was necessary because of leukopenia or elevation in liver enzymes. RESULTS: In the year before treatment with IFN-beta 1a patients had 2.7 +/- 0.93 acute attacks, after treatment the mean number of acute attacks per year was reduced to 1.94 +/- 2.39 (28.9% reduction). When analyzed by gender there was a 62.9% reduction in acute episodes per year in women and a 27.7% reduction in men (p < 0.05). The most frequent side effects were fatigue, headache, local skin reactions, depressed mood, myalgia, weight variations and somnolence. A few patients developed leukopenia, anemia or elevated liver enzymes. In 31.25% of the patients there was an increase in the number of lesions on MRI, in 31.25% there was a reduction in the number of lesions and in 37.5% no change was noted. CONCLUSION: The best-tolerated dose of IFN-beta 1a was 12 million units/week in women and 18 million units/week in men.

Adjuvants, Immunologic↗
PubMedDate not supplied

[Antileukocyte antibodies. Synthetic review and experimental data].

An account is given about the results of investigations carried out in repeatedly transfused patients. We observed an increased presence of the antileucocyte antibodies in relation to the repeatedly transfused patients. The work was extended also to the repeatedly pregnancies; in this research it was also observed a sensibly increased presence of the antileucocyte antibodies in relation with the number of the pregnancies.

Agglutination Tests↗
PubMedDate not supplied

[Laboratory tests applied to transfusion problems. Identification of dangerous universal donors and their frequency].

We studied 504 subjects, whose blood group wes O; they were periodic or occasional blood donors from Transfusional Center A.V.I.S., Policlinico "Umberto I", Roma. Our research was based on the principle stated by Gandini: he states that the natural isoagglutinin concentration equal or superior to 1:200 and the presence of hemolytic isoantibodies may make universal donors dangerous. Our results indicated that the percentage of this kind of donors is 27.75%. Sice 17.26% of our studied subjects showed hemolytic antibodies, we consider it is sufficient to identify dangerous donors through a dosage of hemolytic isoantibodies.

Blood Donors↗